Rhythm Pharmaceuticals Inc To Discuss The FDA Approval Of IMCIVREE Call Transcript

Jun 16, 2022 / 09:00PM GMT
Operator

Thank you for standing by, and welcome to the Rhythm Pharmaceuticals Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to turn the call over to your first speaker today, to Mr. David Connolly, Investor Relations and Corporate Communications. Please go ahead, sir.

David Connolly - Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you and thank you for joining us today.

For those of you participating via the conference call, the accompanying slides can be accessed and controlled by going to the Events section of the Investors page on our website at ir.rhythmtx.com. This afternoon, we issued 2 press releases, which are available on our website.

Moving to Slide 2. I'll remind you that this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot